Abstract: The invention encompasses polymorphs of [2-(1H-indol-3-yl)-1H-imidazol-4-yl](3,4,5-trimethoxyphenyl)methanone and salts thereof. These polymorphs are characterized by their x-ray diffraction pattern and DSC thermograms, among other methods. The polymorphs are used in the preparation of pharmaceutical compositions and products.

Abstract: The present invention relates to methods of treating inflammation using compounds that disrupt the cytoskeleton by causing microtubule depolymerization and preventing or reducing the assembly of activated inflammasomes.

Abstract: The invention encompasses polymorphs of [2-(1H-indol-3-yl)-1H-imidazol-4-yl](3,4,5-trimethoxyphenyl)methanone and salts thereof. These polymorphs are characterized by their x-ray diffraction pattern and DSC thermograms, among other methods. The polymorphs are used in the preparation of pharmaceutical compositions and products.

Abstract: The present invention relates to methods of treating specific viral infections using compounds having anti-tubulin or tubulin disruption activity.

Abstract: The present invention relates to methods of treating coronavirus infections using compounds having anti-tubulin or tubulin disruption activity.

Abstract: This invention relates to pharmaceutical compositions comprising a selective androgen receptor modulator (SARM) compound of Formulae I-XIV and an additional therapeutic agent and uses thereof for treating a breast cancer. The method of the treatment of the invention, in some embodiments, further comprises a step, prior to the treatment, of prescreening a breast cancer subject for whether the breast cancer is susceptible to selective androgen receptor modulator (SARM) treatment.

Abstract: The present invention relates to methods of treating coronavirus infections using compounds having anti-tubulin or tubulin disruption activity.

Abstract: This invention relates to methods of prescreening and treatment of a breast cancer in a subject, and the subject can be either a male or female subject, including methods of prescreening then treating: metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed treatments with selective estrogen receptor modulator (SERM) (tamoxifen, toremifene, raloxifene), gonadotropin-releasing hormone (GnRH) agonist (goserelin), aromatase inhibitor (AI) (letrozole, anastrozole, exemestane), fulvestrant, cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor (palbociclib (Ibrance), ribociclib (Kisqali), abemaciclib (Vorzenio), trilaciclib, lerociclib), alpelisib (Piqray) (an inhibitor of phosphatidylinositol-3-kinase subunit alpha (PI3K?)), mTOR inhibitor (everolimus), poly ADP ribose polymerase (PARP) inhibitor

Abstract: The present invention relates to methods of treating coronavirus infections using compounds having anti-tubulin or tubulin disruption activity.

Abstract: The present invention encompasses methods of treating triple negative breast cancer and/or ovarian cancer using therapeutically effective amounts of compounds represented by the structure of formula I.